908267-60-7

Usage

Uses

Used in Organic Synthesis:
7-chloro-3-iodoH-imidazo[1,2-a]pyridine is used as a key intermediate in organic synthesis for the development of new chemical entities. Its strong nucleophilic and electrophilic properties allow for versatile reactions, facilitating the construction of complex molecular structures.
Used in Pharmaceutical Research:
In pharmaceutical research, 7-chloro-3-iodoH-imidazo[1,2-a]pyridine serves as a valuable reagent for the synthesis of potential drug candidates. Its unique structure and reactivity make it instrumental in the design and development of new drugs and other bioactive compounds, contributing to advancements in medicinal chemistry.
Used in the Development of Bioactive Compounds:
7-chloro-3-iodoH-imidazo[1,2-a]pyridine is employed as a precursor in the creation of bioactive compounds across various fields, including but not limited to, agrochemicals, materials science, and environmental chemistry. Its role in these applications is to provide a foundation for the synthesis of molecules with specific biological activities or properties.

Upstream product

• 4532-25-6 7-chloroimidazo-[1,2-a]pyridine 
• 516-12-1 N-iodo-succinimide 
• 19798-80-2 2-Amino-4-chloropyridine 
• 130721-78-7 tert-butyl (4-chloropyridin-2-yl) carbamate 

Downstream Products

• 1421589-68-5 7-chloro-3-(4-ethoxyphenyl)imidazo[1,2-a]pyridine 
• 1345687-68-4 ethyl [4-(7-chloroimidazo[1,2-a]pyridin-3-yl)phenoxy]acetate 
• 1431163-23-3 C₁₉H₃₁ClN₂Sn 
• 1201653-86-2 N-(2-diethylamino-ethyl)-2-[4-(3-{3-[3-(2,2,2-trifluoro-ethyl)-ureido]-phenyl}-imidazo[1,2-a]pyridin-7-yl)-pyrazol-1-yl]-isobutyramide 
• 1201653-07-7 1-{3-[7-(6-piperidin-1-yl-pyridazin-3-yl)-imidazo[1,2-a]pyridin-3-yl]phenyl}-3-(2,2,2-trifluoroethyl)urea 
• 1201652-95-0 1-(3-{7-[5-(tetrahydrofuran-2-yl)-[1,3,4]thiadiazol-2-yl]imidazo[1,2-a]pyridin-3-yl}-phenyl)-3-(2,2,2-trifluoroethyl)urea 
• 1201652-97-2 2-methyl-2-[4-(3-{3-[3-(2,2,2-trifluoroethyl)ureido]phenyl}imidazo[1,2-a]pyridin-7-yl)pyrazol-1-yl]propionic acid ethyl ester 
• 1201653-24-8 1-(2,2,2-trifluoroethyl)-3-{3-[7-(5-trifluoromethyl[1,3,4]thiadiazol-2-yl)-imidazo[1,2-a]pyridin-3-yl]phenyl}urea 
• 1201653-03-3 2-methyl-2-[4-(3-{3-[3-(2,2,2-trifluoroethyl)ureido]phenyl}imidazo[1,2-a]pyridin-7-yl)pyrazol-1-yl]propionic acid 
• 1201653-10-2 1-(3-{7-[1-(2-hydroxy-1,1-dimethylethyl)-1H-pyrazol-4-yl]-imidazo[1,2-a]pyridin-3-yl}phenyl)-3-(2,2,2-trifluoroethyl)urea 
• 1201653-15-7 1-{3-[7-(3-methyl-3H-imidazol-4-ylethynyl)imidazo[1,2-a]pyridin-3-yl]phenyl}-3-(2,2,2-trifluoroethyl)urea 
• 1201653-11-3 1-[3-(7-pyridin-3-ylethynylimidazo[1,2-a]pyridin-3-yl)phenyl]-3-(2,2,2-trifluoroethyl)urea 
• 1201654-55-8 1-(3-{7-[2-(3-methyl-3H-imidazol-4-yl)-ethyl]-imidazo[1,2-a]pyridin-3-yl}-phenyl)-3-(2,2,2-trifluoro-ethyl)-urea 
• 1201652-99-4 1-[3-(7-pyridin-2-ylimidazo[1,2-a]pyridin-3-yl)phenyl]-3-(2,2,2-trifluoroethyl)urea 

Relevant academic research and scientific papers

From Synthetic Simplified Marine Metabolite Analogues to New Selective Allosteric Inhibitor of Aurora B Kinase

Significant inhibition of Aurora B was achieved by the synthesis of simplified fragments of benzosceptrins and oroidin belonging to the marine pyrrole-2-aminoimidazoles metabolites isolated from sponges. Evaluation of kinase inhibition enabled the discovery of a synthetically accessible rigid acetylenic structural analogue EL-228 (1), whose structure could be optimized into the potent CJ2-150 (37). Here we present the synthesis of new inhibitors of Aurora B kinase, which is an important target for cancer therapy through mitosis regulation. The biologically oriented synthesis yielded several nanomolar inhibitors. The optimized compound CJ2-150 (37) showed a non-ATP competitive allosteric mode of action in a mixed-type inhibition for Aurora B kinase. Molecular docking identified a probable binding mode in the allosteric site "F"and highlighted the key interactions with the protein. We describe the improvement of the inhibitory potency and specificity of the novel scaffold as well as the characterization of the mechanism of action.

FUSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS

The present invention provides small molecule inhibitors of BMP signaling that are useful for treating diseases or conditions associated with BMP signaling, including cancers of the central nervous system.

Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinome

Using a structure based design approach we have identified a series of indazole substituted pyrrolopyrazines, which are potent inhibitors of JAK3. Intramolecular electronic repulsion was used as a strategy to induce a strong conformational bias within the ligand. Compounds bearing this conformation participated in a favorable hydrophobic interaction with a cysteine residue in the JAK3 binding pocket, which imparted high selectivity versus the kinome and improved selectivity within the JAK family.

Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole and related heterocycles

A series of potent arenavirus inhibitors sharing a benzimidazole core were previously reported by our group. SAR studies were expanded beyond the previous analysis, which involved the attached phenyl rings and methylamino linker portion, to include modifications focused on the benzimidazole core. These changes included the introduction of various substituents to the bicyclic benzimidazole ring system along with alternate core heterocycles. Many of the analogs containing alternate nitrogen-based bicyclic ring systems were found to retain antiviral potency compared to the benzimidazole series from which we derived our lead compound, ST-193. In fact, 21h, built on an imidazopyridine core, possessed a near tenfold increase in potency against Lassa virus pseudotypes compared to ST-193. As found with the benzimidazole series, broad-spectrum arenavirus activity was also observed for a number of the analogs discovered during this study.

[5,6]HETEROCYCLIC COMPOUND

Abstract: An object of the present invention is to provide a novel low molecular weight compound exhibiting an osteogenesis-promoting action. This object is achieved by a compound having the general formula (I) or a pharmacologically acceptable salt thereof. In the general formula (I), R1 and R2 represent hydrogen atoms, and the like; R3 represents a hydrogen atom, and the like; X, Y, and Z represent nitrogen atoms, and the like; A represents a phenylene group, and the like; n represents 1 or 2, and the like; and V and W represent oxygen atoms, and the like.

ANTIVIRAL DRUGS FOR TREATMENT OF ARENA VIRUS INFECTION

Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by the Arenavirus family such as Lassa fever, Argentine hemorrhagic fever, Bolivian hemorrhagic fever, and Venezuelan hemorrhagic fever

IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES

The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS

The invention relates to new bicyclic heterocyclic derivative compounds of formula (I): wherein R1, A, X1, X2, X3, X4, X5 and R2 are as defined herein, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

NEW COMPOUNDS

The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

IMIDAZO (1, 2-A) PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS

The present invention provides compounds that are inhibitors of VEGF-R2 of the formula: (I) and methods of using these compounds.